STAT+: To help migraine patients — and sell more medicines — major drugmakers turn to telehealth
In 2021, Katey Frederking had reached the end of her rope. The 29-year-old was struggling…
Category: biotechnology
A Galapagos investor signals impatience with its turnaround efforts
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Tome Biosciences files notice to lay off nearly entire staff
High-profile gene editing startup Tome Biosciences said in a legal filing Friday that it will…
Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides
What does the hiring of a well-known industry dealmaker mean for the future of BioMarin…
STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering
Buzzy gene-editing startup Tome Biosciences is floundering, just nine months after launching with $213 million…
STAT+: What to know about Alnylam’s upcoming readout on its heart drug
Next week, the biopharma world will see eagerly awaited results from a trial that could…
STAT+: AI drug firm Recursion moves from survival to industry domination
SALT LAKE CITY — On paper, Recursion Pharmaceuticals shouldn’t have worked. The company — or, at…
Is pharma still fearful of the Inflation Reduction Act?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pfizer and BioNTech effort to develop Covid-influenza combination vaccine sees setback
Pfizer and BioNTech said Friday that their combined mRNA vaccine candidate against influenza and Covid-19…
STAT+: Boston’s lab market is in as rough shape
When demand for office space cratered during the Covid-19 pandemic, many developers in the Boston…
STAT+: The business of CRISPR’d medicine: Not great
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
We have mpox vaccines now. But how will they be distributed?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Gilead wins U.S. approval for drug to treat autoimmune liver disease
The Food and Drug Administration on Wednesday approved a new treatment for primary biliary cholangitis,…
Syros shares battered after it stops leukemia trial
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Atai advances oral psychedelic in depression
Want to stay on top of the science and politics driving biotech today? Sign up to get…
A tough week for MDMA-assisted psychotherapy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Why did Novo pull heart failure paperwork for Wegovy?
Hey, humans. Today, we talk about the decades-long pursuit to get MDMA approved as a…
Listen: VC struggles, drug pricing negotiations, & Novo’s abrupt Wegovy decision
Why did Novo Nordisk pull its paperwork to expand the use of Wegovy for a…
STAT+: A strong start for Madrigal’s MASH drug launch
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: AI drug developers Recursion, Exscientia to merge
Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia,…
Sarepta CEO: We’re ‘pretty brilliant’
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Vertex, U.K. reach deal to provide CRISPR-based medicine to thalassemia patients in England
LONDON — Patients in England with a rare blood disorder will now be able to…
A new drug for glioma means a windfall for Agios
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The exclusive biotech stories you need to read
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biotech mogul Arie Belldegrun extends empire with launch of $600 million credit firm
Arie Belldegrun has yet another job: He wants to be your lender. On Tuesday, Belledegrun…
STAT+: Former Biden White House health official joins Flagship Pioneering
WASHINGTON — Raj Panjabi has made a career out of taking on some of public…
STAT+: Biotech VCs are pacing for another record-low year of fundraising amid glimpses of recovery
Life science venture capital firms are pacing for another record-low year of fundraising, potentially hindering…
STAT+: BioMarin to restrict sales of hemophilia gene therapy, seeking to overcome slow sales
Struggling to find new patients, BioMarin Pharmaceuticals on Monday said it would restrict sales of…
FDA ad comm favors Zevra’s Niemann-Pick drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Moderna is still in a Covid hangover
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: FDA approves innovative T cell immunotherapy for rare soft-tissue cancer
LONDON — U.S. regulators have authorized a cutting-edge treatment relying on T cells for a…
.jpg)
STAT+: On Andrew Left and the government’s fraud case
I love the Summer Olympics. Every four years I transform into a huge fan of…
STAT+: Jim Wilson, gene therapy pioneer, departs Penn to set up new companies
Jim Wilson, a leading gene therapy researcher who has persisted through the field’s ups and…
venBio raises $528 million for its fifth fund
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: With new data, RegenxBio advances plan for Duchenne gene therapy
Regenxbio said Thursday that its experimental gene therapy for Duchenne muscular dystrophy was administered to…
The debate over how long to use Alzheimer’s drugs
Good morning. We have a new investigation out today about how Mount Sinai in New…
Opinion: DNA data security requires robust protections, not rhetoric
The BIOSECURE Act, now rolling through Congress, aims to protect the DNA data of Americans…
STAT+: Eisai, Biogen make case for long-term use of Alzheimer’s drug Leqembi with new data
Patients with early Alzheimer’s disease treated with a medication developed by Eisai and Biogen for…
STAT+: Merck shares fall as sales of HPV vaccine drop in China
Shares of Merck fell 9% Tuesday after the company reported that in the second quarter,…
Testing GLP-1s in Alzheimer’s, and is Medicare a good negotiator?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Older GLP-1 drug may help protect brains of Alzheimer’s patients, early study suggests
A new study suggests that an older GLP-1 drug may help protect the brains of…
Opinion: How artificial intelligence can bolster Europe’s competitive edge in biopharma
In a year marked by European Parliament elections and setting of the European Union’s priorities…
STAT+: Parasite engineered to treat brain development disorder in mice shows potential in study
The human body works hard to prevent outside substances from entering the brain — which…
Blood tests for Alzheimer’s diagnosis were 91% accurate in new study
New blood tests could help doctors diagnose Alzheimer’s disease faster and more accurately, researchers reported Sunday –…
The biotech news you need from the weekend
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Bird flu snapshot: Upstart manufacturers in low- and middle-income countries to start early vaccine work
Bird flu snapshot: This is the latest installment in a series of regular updates on…
STAT+: Sarepta demanded Duchenne patient advocacy group censor video critical of the company
Sarepta Therapeutics demanded a prominent patient advocacy organization censor a video that contained pointed criticism…
The worst for Dexcom may not be over
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: European regulators say Alzheimer’s therapy Leqembi should be rejected
LONDON — European regulators on Friday said that an Alzheimer’s therapy from Eisai and Biogen…
Roche CEO explains the company’s weight loss drug strategy in crowded market
LONDON — In the booming field of weight loss drugs, Roche has been riding high…